What is Dragons Die?
Imagine an autobattler where every single unit you love is guaranteed to die, and their remains are the only way to get stronger. Dragons Die turns the genre into a moody, permadeath struggle to carry your flight home.
Gameplay
You're not just building a board and hoping for the best here. In Dragons Die, you manage a flight of named dragons, but the core loop is built around the fact that they're all going to die. You hunt the reach, fight battles, and eventually lose your favorites. It's a permadeath strategy game where death actually fuels your progress; you use the bones of your fallen dragons to arm the next flight. It's a heavy cycle of loss and rebuilding that makes every unit feel personal.
It's a complete departure from the vibe of TFT or Battlegrounds. Instead of chasing a meta, you're dealing with the emotional weight of the 'long table' that remembers everyone who didn't come home. You've also got Peggs, a small dragon who minds the eggs, keeping the cycle moving. The progression is tied to this legacy system, which keeps you coming back even when a run ends in disaster.
At $4.99, it's a paid title in a genre dominated by free-to-play giants. For most, it's a steal given the unique atmosphere, but you'll notice it doesn't have the polished sheen of a AAA autobattler. It's a tighter, more intimate experience. If you're looking for massive rosters or complex economy pivoting, you might find the scope a bit limited. It's more about the mood and the grind of survival than high-level competitive optimization.
Key Features
- Bones of fallen dragons arm successors
- Permadeath strategy with named units
- Legacy system via the long table
- Egg management with Peggs
Screenshots
Verdict
Grab this if you want a moody, emotional twist on strategy and don't mind a paid entry fee. Skip it if you only care about competitive ladders or need a massive amount of mechanical depth to stay interested.
View on Steam →* Price at time of publication (checked 15.07.2026). Prices may vary by region and are subject to change. This is an editorial review, not a commercial offer.